Recent Company News

• 09:42 AM ET Dec 06, 2025
  

  Johnson & Johnson announces updated results from the Phase 3 CARTITUDE-4 study which demonstrated lasting treatment-free remissions at 2.5 years in patients with RRMM ($201.93, 0.00)

• 01:41 PM ET Dec 05, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 07-Dec

• 11:44 AM ET Nov 28, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 30-Nov

• 09:00 AM ET Nov 27, 2025
  

  Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

• 01:53 PM ET Nov 24, 2025
  

  ASH posts late-breaker abstract of results from Johnson & Johnson's Phase 3 MajesTEC-3 study of teclistamab in R/R multiple myeloma (~12:00ET) ($204.81, +0.91)

• 12:42 PM ET Nov 12, 2025
  

  Transcript Intelligence: Legend Biotech Q3 Earnings Guidance ($30.01, -2.02)

• 12:42 PM ET Nov 12, 2025
  

  Transcript Intelligence: Legend Biotech Q3 Earnings Themes ($30.00, -2.03)

• 12:42 PM ET Nov 12, 2025
  

  Transcript Intelligence: Legend Biotech Q3 Earnings Q&A ($29.98, -2.06)

• 08:18 AM ET Nov 12, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:06 AM ET Nov 12, 2025
  

  Legend Biotech reports Q3 EPS ($0.11) vs FactSet ($0.07) [13 est, ($0.24)-0.03] - 6-K ($32.03, 0.00)